Fyarro Approved for Malignant Perivascular Epithelioid Cell Tumor
The approval of Fyarro, an mTOR inhibitor, was based on data from the phase 2 AMPECT study, which included 34 adults with advanced malignant PEComa.
Sarcoma
Nanoparticle Albumin-Bound mTOR Inhibitor Gets Priority Review for Ultra-Rare Sarcoma
Nab-sirolimus is an mTOR inhibitor bound to human albumin.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
